Who are contrast agent (iodixanol)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Iodixanol (Visipaque), VISIPAQUE 270, Visipaque - Hydrocortancyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/contrast-agent-iodixanol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

contrast agent (iodixanol) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

contrast agent (iodixanol) (contrast agent (iodixanol)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-ionic iso-osmolar contrast medium. Area: Diagnostic Imaging.

marketed Non-ionic iso-osmolar contrast medium Diagnostic Imaging Small molecule Live · refreshed every 30 min

Target snapshot

contrast agent (iodixanol) (contrast agent (iodixanol)) — Seoul National University Bundang Hospital. Iodixanol is a non-ionic, iso-osmolar contrast medium that provides radiographic visualization of blood vessels and organs by absorbing X-rays due to its high iodine content.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
contrast agent (iodixanol) TARGET	contrast agent (iodixanol)	Seoul National University Bundang Hospital	marketed	Non-ionic iso-osmolar contrast medium
Iodixanol (Visipaque)	Iodixanol (Visipaque)	Chinese PLA General Hospital	marketed	Non-ionic iso-osmolar contrast medium
VISIPAQUE 270	VISIPAQUE 270	Bracco Diagnostics, Inc	marketed	Non-ionic iso-osmolar contrast medium
Visipaque - Hydrocortancyl	Visipaque - Hydrocortancyl	Assistance Publique - Hôpitaux de Paris	marketed	Non-ionic iso-osmolar contrast medium

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-ionic iso-osmolar contrast medium class)

Assistance Publique - Hôpitaux de Paris · 1 drug in this class
Bracco Diagnostics, Inc · 1 drug in this class
Chinese PLA General Hospital · 1 drug in this class
Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). contrast agent (iodixanol) — Competitive Intelligence Brief. https://druglandscape.com/ci/contrast-agent-iodixanol. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing